Oral treatment of late Lyme borreliosis with a combination of roxithromycin and co-trimoxazole--a pilot study on 18 patients.
In this pilot trial, 18 patients participated in an investigation in which the combined therapy of co-trimoxazole and roxithromycin in late Lyme borreliosis was tested. The study has been performed as a result of earlier case reports in "The Lancet" where this combination has been used successfully in order to thwart late Lyme disease. The authors show that 76% of the patients recovered completely. In 2 patients, symptoms could be resolved with i.v. penicillin and 2 did not respond to any antibiotic therapy. These results show that oral therapy of co-trimoxazole and roxithromycin in combination provides similar results as i.v. antibiotics in earlier studies.
Gasser
R
R
Department of Internal Medicine, University Graz.
Reisinger
E
E
Sedaj
B
B
Horvarth
R
R
Seinost
G
G
Keplinger
A
A
Wendelin
I
I
Klein
W
W
D000284:Administration, Oral; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008193:Lyme Disease / Q000175:diagnosis / Q000188:drug therapy*; D010865:Pilot Projects; D015575:Roxithromycin / Q000009:adverse effects / Q000627:therapeutic use*; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000009:adverse effects / Q000627:therapeutic use*
D015575:Roxithromycin; D015662:Trimethoprim, Sulfamethoxazole Drug Combination